Search

Your search keyword '"Della-Torre E"' showing total 812 results
Start Over Author "Della-Torre E"
812 results on '"Della-Torre E"'

3. POS0347 INSIGHTS INTO THE DESIGN AND STUDY POPULATION OF MITIGATE: THE FIRST MULTINATIONAL RANDOMIZED CONTROLLED CLINICAL TRIAL IN IgG4 RELATED DISEASE (IgG4-RD), EVALUATING THE EFFICACY AND SAFETY OF INEBILIZUMAB

Author

Stone, J. H., primary, Culver, E. L., additional, Khosroshahi, A., additional, Zhang, W., additional, Della Torre, E., additional, Okazaki, K., additional, Tanaka, Y., additional, Lohr, M., additional, Schleinitz, N., additional, Dong, L., additional, Umehara, H., additional, Lanzillotta, M., additional, Wallace, Z. S., additional, Ebbo, M., additional, Webster, G., additional, Wu, Y., additional, Cimbora, D., additional, and Rampal, N., additional

Published
2024
Full Text
View/download PDF

6. Premessa

Author

Corradini, M, Senna, P, Galasso, L, Rossini, F, Forner, F, Cattaneo, A, Giudice, F, Carpani, R: Squizzato, A, Della Torre, E, Corradini, Marco Maria, Corradini Marco (ORCID:0000-0002-4193-7970), Corradini, M, Senna, P, Galasso, L, Rossini, F, Forner, F, Cattaneo, A, Giudice, F, Carpani, R: Squizzato, A, Della Torre, E, Corradini, Marco Maria, and Corradini Marco (ORCID:0000-0002-4193-7970)

Abstract

Premessa generale alla raccolta degli Atti della Giornata di studi sulle edizioni del Settecento nella Biblioteca dell'Università Cattolica di Milano, General introduction to the collection of the Proceedings of the Study Day on eighteenth-century editions in the Library of the Catholic University of Milan

Published
2024

7. Electric-field Controlled Magnetization Switching in Co/Pt thin-Film Ferromagnets

Author

Siddique, A., Gu, S., Witte, R., Ghahremani, M., Nwokoye, C. A., Aslani, A., Kruk, R., Provenzano, V., Bennett, L. H., and Della Torre, E.

Subjects
Condensed Matter - Materials Science, Condensed Matter - Mesoscale and Nanoscale Physics
Abstract

A study of dynamic and reversible voltage controlled magnetization switching in ferromagnetic Co/Pt thin film with perpendicular magnetic anisotropy at room temperature is presented. The change in the magnetic properties of the system is observed in a relatively thick film of 15 nm. A surface charge is induced by the formation of electrochemical double layer between the metallic thin film and non-aqueous lithium LiClO4 electrolyte to manipulate the magnetism. The change in the magnetic properties occurred by the application of an external electric field. As the negative voltage was increased, the coercivity and the switching magnetic field decreased thus activating magnetization switching. The results are envisaged to lead to faster and ultra-low power magnetization switching as compared to spin-transfer torque (STT) switching in spintronic devices., Comment: 5 pages, 8 figures

Published
2015

8. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Author

Talarico, R, Ramirez, G, Barreira, S, Cardamone, C, Triggianese, P, Aguilera, S, Andersen, J, Avcin, T, Benistan, K, Bertsias, G, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Callens, S, Carreira, P, Cervera, R, Cutolo, M, Damian, L, Della-Torre, E, Faria, R, Fonseca, J, Galetti, I, Hachulla, E, Iaccarino, L, Jacobsen, S, Khmelinskii, N, Limper, M, Marinello, D, Meyer, A, Moroncini, G, Nagy, G, Olesinska, M, Pamfil, C, Pileckyte, M, Pistello, M, Rednic, S, Richez, C, Romao, V, Schneider, M, Sciascia, S, Scire, C, Simonini, G, Smith, V, Sulli, A, Tani, C, Tas, S, Tincani, A, Vonk, M, Tektonidou, M, Mosca, M, Talarico R., Ramirez G. A., Barreira S. C., Cardamone C., Triggianese P., Aguilera S., Andersen J., Avcin T., Benistan K., Bertsias G., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Callens S., Carreira P. E., Cervera R., Cutolo M., Damian L., Della-Torre E., Faria R., Fonseca J. E., Galetti I., Hachulla E., Iaccarino L., Jacobsen S., Khmelinskii N., Limper M., Marinello D., Meyer A., Moroncini G., Nagy G., Olesinska M., Pamfil C., Pileckyte M., Pistello M., Rednic S., Richez C., Romao V. C., Schneider M., Sciascia S., Scire C. A., Simonini G., Smith V., Sulli A., Tani C., Tas S. W., Tincani A., Vonk M. C., Tektonidou M., Mosca M., Talarico, R, Ramirez, G, Barreira, S, Cardamone, C, Triggianese, P, Aguilera, S, Andersen, J, Avcin, T, Benistan, K, Bertsias, G, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Callens, S, Carreira, P, Cervera, R, Cutolo, M, Damian, L, Della-Torre, E, Faria, R, Fonseca, J, Galetti, I, Hachulla, E, Iaccarino, L, Jacobsen, S, Khmelinskii, N, Limper, M, Marinello, D, Meyer, A, Moroncini, G, Nagy, G, Olesinska, M, Pamfil, C, Pileckyte, M, Pistello, M, Rednic, S, Richez, C, Romao, V, Schneider, M, Sciascia, S, Scire, C, Simonini, G, Smith, V, Sulli, A, Tani, C, Tas, S, Tincani, A, Vonk, M, Tektonidou, M, Mosca, M, Talarico R., Ramirez G. A., Barreira S. C., Cardamone C., Triggianese P., Aguilera S., Andersen J., Avcin T., Benistan K., Bertsias G., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Callens S., Carreira P. E., Cervera R., Cutolo M., Damian L., Della-Torre E., Faria R., Fonseca J. E., Galetti I., Hachulla E., Iaccarino L., Jacobsen S., Khmelinskii N., Limper M., Marinello D., Meyer A., Moroncini G., Nagy G., Olesinska M., Pamfil C., Pileckyte M., Pistello M., Rednic S., Richez C., Romao V. C., Schneider M., Sciascia S., Scire C. A., Simonini G., Smith V., Sulli A., Tani C., Tas S. W., Tincani A., Vonk M. C., Tektonidou M., and Mosca M.

Abstract

Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient's representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final OP

Published
2023

12. The impact of a multidisciplinary team evaluation on the diagnosis and management of acute and chronic pancreatitis in a tertiary referral center

Author

Lauri, G., additional, Tacelli, M., additional, Belfiori, G., additional, Palumbo, D., additional, Aleotti, F., additional, Lanzillotta, M., additional, Ponz de Leon Pisani, R., additional, Bina, N., additional, Dell'Anna, G., additional, Zaccari, P., additional, Vanella, G., additional, Archibugi, L., additional, Balzano, G., additional, Petrone, M. C., additional, Rossi, G., additional, Tamburrino, D., additional, Mariani, A., additional, Doglioni, C., additional, Della Torre, E., additional, De Cobelli, F., additional, Falconi, M., additional, Arcidiacono, P. G., additional, Crippa, S., additional, and Capurso, G., additional

Published
2023
Full Text
View/download PDF

13. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products.

Author

Talarico, R., Ramirez, G.A., Barreira, S.C., Cardamone, C., Triggianese, P., Aguilera, S., Andersen, J., Avcin, T., Benistan, K., Bertsias, G., Bortoluzzi, A., Bouillot, C., Bulina, I., Burmester, G.R., Callens, S., Carreira, P.E., Cervera, R., Cutolo, M., Damian, L., Della-Torre, E., Faria, R., Fonseca, J.E., Galetti, I., Hachulla, E., Iaccarino, L., Jacobsen, S., Khmelinskii, N., Limper, M., Marinello, D., Meyer, A, Moroncini, G., Nagy, G., Olesinska, M., Pamfil, C., Pileckyte, M., Pistello, M., Rednic, S., Richez, C., Romão, V.C., Schneider, M., Sciascia, S., Scirè, C.A., Simonini, G., Smith, V., Sulli, A., Tani, C., Tas, S.W., Tincani, A., Vonk, M.C., Tektonidou, M., Mosca, M., Talarico, R., Ramirez, G.A., Barreira, S.C., Cardamone, C., Triggianese, P., Aguilera, S., Andersen, J., Avcin, T., Benistan, K., Bertsias, G., Bortoluzzi, A., Bouillot, C., Bulina, I., Burmester, G.R., Callens, S., Carreira, P.E., Cervera, R., Cutolo, M., Damian, L., Della-Torre, E., Faria, R., Fonseca, J.E., Galetti, I., Hachulla, E., Iaccarino, L., Jacobsen, S., Khmelinskii, N., Limper, M., Marinello, D., Meyer, A, Moroncini, G., Nagy, G., Olesinska, M., Pamfil, C., Pileckyte, M., Pistello, M., Rednic, S., Richez, C., Romão, V.C., Schneider, M., Sciascia, S., Scirè, C.A., Simonini, G., Smith, V., Sulli, A., Tani, C., Tas, S.W., Tincani, A., Vonk, M.C., Tektonidou, M., and Mosca, M.

Abstract

Item does not contain fulltext, Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient's representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final OP

Published
2023

15. OC.09.4 THE IMPACT OF A MULTIDISCIPLINARY TEAM EVALUATION ON THE DIAGNOSIS AND MANAGEMENT OF ACUTE AND CHRONIC PANCREATITIS IN A TERTIARY REFERRAL CENTER

Author

Lauri, G., primary, Tacelli, M., additional, Palumbo, D., additional, Aleotti, F., additional, Lanzillotta, M., additional, Ponz De Leon Pisani, R., additional, Bina, N., additional, Dell'Anna, G., additional, Zaccari, P., additional, Vanella, G., additional, Archibugi, L., additional, Balzano, G., additional, Petrone, M.C., additional, Rossi, G., additional, Tamburrino, D., additional, Mariani, A., additional, Doglioni, C., additional, Della Torre, E., additional, De Cobelli, F., additional, Falconi, M., additional, Arcidiacono, P., additional, Crippa, S., additional, and Capurso, G., additional

Published
2023
Full Text
View/download PDF

18. Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

Author

Overbeek, Kasper A., primary, Poulsen, J., additional, Lanzillotta, M., additional, Vinge-Holmquist, O., additional, Macinga, P., additional, Demirci, A., additional, Sindhunata, D., additional, Backhus, J., additional, Algül, H., additional, Buijs, J., additional, Levy, P., additional, Kiriukova, M., additional, Goni, E., additional, Hollenbach, M., additional, Miksch, R., additional, Kunovský, L., additional, Vujasinovic, M., additional, Nikolic, S., additional, Dickerson, L., additional, Hirth, M., additional, Neurath, M., additional, Zumblick, M., additional, Vila, J., additional, Jalal, M., additional, Beyer, G., additional, Frost, F., additional, Carrara, S., additional, Kala, Z., additional, Jabandžiev, P., additional, Sisman, G., additional, Akyuz, F., additional, Capurso, G., additional, Falconi, M., additional, Arlt, A., additional, Vleggaar, F., additional, Barresi, L., additional, Greenhalf, B., additional, Czakó, L., additional, Hegyi, P., additional, Hopper, A., additional, Nayar, M., additional, Gress, T., additional, Vitali, F., additional, Schneider, A., additional, Halloran, C., additional, Trna, J., additional, Okhlobystin, A., additional, Dagna, L., additional, Cahen, D., additional, Bordin, D., additional, Rebours, V., additional, Mayerle, J., additional, Kahraman, A., additional, Rasch, S., additional, Culver, E., additional, Kleger, A., additional, Martínez-Moneo, E., additional, Røkke, O., additional, Hucl, T., additional, Olesen, S., additional, Bruno, M., additional, Della-Torre, E., additional, Beuers, U., additional, Löhr, J., additional, and Rosendahl, J., additional

Published
2022
Full Text
View/download PDF

22. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Author

De Luca G., Cavalli G., Campochiaro C., Della-Torre E., Angelillo P., Tomelleri A., Boffini N., Tentori S., Mette F., Farina N., Rovere-Querini P., Ruggeri A., D'Aliberti T., Scarpellini P., Landoni G., De Cobelli F., Paolini J. F., Zangrillo A., Tresoldi M., Trapnell B. C., Ciceri F., Dagna L., DE LUCA , GIACOMO, De Luca, G., Cavalli, G., Campochiaro, C., Della-Torre, E., Angelillo, P., Tomelleri, A., Boffini, N., Tentori, S., Mette, F., Farina, N., Rovere-Querini, P., Ruggeri, A., D'Aliberti, T., Scarpellini, P., Landoni, G., De Cobelli, F., Paolini, J. F., Zangrillo, A., Tresoldi, M., Trapnell, B. C., Ciceri, F., Dagna, L., and DE LUCA, Giacomo

Subjects
Mechanical ventilation, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, medicine.medical_treatment, Immunology, medicine.disease, Article, Blockade, Single centre, Pneumonia, Mavrilimumab, Rheumatology, Internal medicine, medicine, Immunology and Allergy, Prospective cohort study, Adverse effect, business
Abstract

Summary Background Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte–macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation. Methods This single-centre prospective cohort study included patients aged 18 years or older who were admitted to San Raffaele Hospital (Milan, Italy) with severe COVID-19 pneumonia, hypoxia, and systemic hyperinflammation. Patients received a single intravenous dose (6 mg/kg) of mavrilimumab added to standard care given by the hospital at the time. The control group consisted of contemporaneous patients with similar baseline characteristics who received standard care at the same hospital. The main outcome was time to clinical improvement (defined as improvement of two or more points on the seven-point ordinal scale of clinical status). Other outcomes included proportion of patients achieving clinical improvement, survival, mechanical ventilation-free survival, and time to fever resolution. Adverse events were monitored daily. Findings Between March 17 and April 15, 2020, 13 non-mechanically ventilated patients (median age 57 years [IQR 52–58], 12 [92%] men) received mavrilimumab and 26 patients (median age 60 [IQR 53–67], 17 [65%] men) in the control group received standard care. During the 28-day follow-up, no patients in the mavrilimumab group died, and seven (27%) patients in the control group died (p=0·086). At day 28, all patients in the mavrilimumab group and 17 (65%) patients in the control group showed clinical improvement (p=0·030), with earlier improvement in the mavrilimumab than in the control group (mean time to improvement 8 days [IQR 5 to 11] vs 19 days [11 to >28], p=0·0001). By day 28, one (8%) patient in the mavrilimumab group progressed to mechanical ventilation compared with nine (35%) patients in the control group who progressed to mechanical ventilation or died (p=0·14). By day 14, fever resolved in ten (91%) of 11 febrile patients in the mavrilimumab group, compared with 11 (61%) of 18 febrile patients in the control group (p=0·18); fever resolution was faster in mavrilimumab recipients versus controls (median time to resolution 1 day [IQR 1 to 2] vs 7 days [3 to >14], p=0·0093). Mavrilimumab was well tolerated, with no infusion reactions. Three (12%) patients in the control group developed infectious complications. Interpretation Mavrilimumab treatment was associated with improved clinical outcomes compared with standard care in non-mechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation. Treatment was well tolerated. Confirmation of efficacy requires controlled testing. Funding IRCCS San Raffaele Scientific Institute.

Published
2020

23. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Author

Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, Tomelleri A, Farina N, Ruggeri A, Rovere-Querini P, Di Lucca G, Martinenghi S, Scotti R, Tresoldi M, Ciceri F, Landoni G, Zangrillo A, Scarpellini P, Dagna L, DE LUCA , GIACOMO, Cavalli, G, De Luca, G, Campochiaro, C, Della-Torre, E, Ripa, M, Canetti, D, Oltolini, C, Castiglioni, B, Tassan Din, C, Boffini, N, Tomelleri, A, Farina, N, Ruggeri, A, Rovere-Querini, P, Di Lucca, G, Martinenghi, S, Scotti, R, Tresoldi, M, Ciceri, F, Landoni, G, Zangrillo, A, Scarpellini, P, Dagna, L, and DE LUCA, Giacomo

Subjects
Mechanical ventilation, ARDS, Anakinra, medicine.medical_specialty, education.field_of_study, business.industry, medicine.medical_treatment, Standard treatment, Immunology, Population, Retrospective cohort study, medicine.disease, Article, Rheumatology, Intensive care, Internal medicine, medicine, Immunology and Allergy, Respiratory function, business, education, medicine.drug
Abstract

Summary Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed maximum capacity of intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation outside of the ICU. Effective treatments for this population are needed urgently. Anakinra is a recombinant interleukin-1 receptor antagonist that might be beneficial in this patient population. Methods We conducted a retrospective cohort study at the San Raffaele Hospital in Milan, Italy. We included consecutive patients (aged ≥18 years) with COVID-19, moderate-to-severe ARDS, and hyperinflammation (defined as serum C-reactive protein ≥100 mg/L, ferritin ≥900 ng/mL, or both) who were managed with non-invasive ventilation outside of the ICU and who received standard treatment of 200 mg hydroxychloroquine twice a day orally and 400 mg lopinavir with 100 mg ritonavir twice a day orally. We compared survival, mechanical ventilation-free survival, changes in C-reactive protein, respiratory function, and clinical status in a cohort of patients who received additional treatment with anakinra (either 5 mg/kg twice a day intravenously [high dose] or 100 mg twice a day subcutaneously [low dose]) with a retrospective cohort of patients who did not receive anakinra (referred to as the standard treatment group). All outcomes were assessed at 21 days. This study is part of the COVID-19 Biobank study, which is registered with ClinicalTrials.gov , NCT04318366 . Findings Between March 17 and March 27, 2020, 29 patients received high-dose intravenous anakinra, non-invasive ventilation, and standard treatment. Between March 10 and March 17, 2020, 16 patients received non-invasive ventilation and standard treatment only and comprised the comparison group for this study. A further seven patients received low-dose subcutaneous anakinra in addition to non-invasive ventilation and standard treatment; however, anakinra treatment was interrupted after 7 days because of a paucity of effects on serum C-reactive protein and clinical status. At 21 days, treatment with high-dose anakinra was associated with reductions in serum C-reactive protein and progressive improvements in respiratory function in 21 (72%) of 29 patients; five (17%) patients were on mechanical ventilation and three (10%) died. In the standard treatment group, eight (50%) of 16 patients showed respiratory improvement at 21 days; one (6%) patient was on mechanical ventilation and seven (44%) died. At 21 days, survival was 90% in the high-dose anakinra group and 56% in the standard treatment group (p=0·009). Mechanical ventilation-free survival was 72% in the anakinra group versus 50% in the standard treatment group (p=0·15). Bacteraemia occurred in four (14%) of 29 patients receiving high-dose anakinra and two (13%) of 16 patients receiving standard treatment. Discontinuation of anakinra was not followed by inflammatory relapses. Interpretation In this retrospective cohort study of patients with COVID-19 and ARDS managed with non-invasive ventilation outside of the ICU, treatment with high-dose anakinra was safe and associated with clinical improvement in 72% of patients. Confirmation of efficacy will require controlled trials. Funding None.

Published
2020
Full Text
View/download PDF

29. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement

Author

Natalello G, De Luca G, Gigante L, Campochiaro C, De Lorenzis E, Verardi L, Paglionico A, Petricca L, Martone AM, Calvisi S, Ripa M, Cavalli G, DELLA TORRE E, Tresoldi M, Landi F, Bosello SL, Gremese E, Dagna L., Natalello, G, De Luca, G, Gigante, L, Campochiaro, C, De Lorenzis, E, Verardi, L, Paglionico, A, Petricca, L, Martone, Am, Calvisi, S, Ripa, M, Cavalli, G, DELLA TORRE, E, Tresoldi, M, Landi, F, Bosello, Sl, Gremese, E, and Dagna, L.

Published
2021

30. Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1)

Author

Spagnuolo V., Guffanti M., Galli L., Poli A., Querini P. R., Ripa M., Clementi M., Scarpellini P., Lazzarin A., Tresoldi M., Dagna L., Zangrillo A., Ciceri F., Castagna A., Andolina A., Redaelli M. B., Baldissera E., Bigai G., Bigoloni A., Boffini N., Borio G., Bossolasco S., Bruzzesi E., Calabro M. G., Calvisi S., Campochiaro C., Canetti D., Canti V., Castellani J., Castiglioni B., Cavalli G., Cavallo L., Cernuschi M., Chiurlo M., Cilla M., Cinel E., Cinque P., Conte C., Da Prat V., Danise A., De Lorenzo R., De Luca G., Dell'Acqua A., Dell'Acqua R., Della-Torre E., Torre L. D., Di Terlizzi G., Dumea I., Farolfi F., Ferrante M., Frangi C., Fumagalli L., Gallina G., Germinario B., Gianotti N., Hasson H., Lalla F., Landoni G., Lanzillotta M., Voti R. L., Mastrangelo A., Messina E., Moizo E., Montagna M., Monti G., Morsica G., Muccini C., Nozza S., Oltolini C., Pascali M., Patrizi A., Pieri M., Prestifilippo D., Ramirez G., Ranzenigo M., Sapienza J., Sartorelli S., Seghi F., Tambussi G., Din C. T., Tomelleri A., Turi S., Uberti-Foppa C., Vinci C., Spagnuolo, V., Guffanti, M., Galli, L., Poli, A., Querini, P. R., Ripa, M., Clementi, M., Scarpellini, P., Lazzarin, A., Tresoldi, M., Dagna, L., Zangrillo, A., Ciceri, F., Castagna, A., Andolina, A., Redaelli, M. B., Baldissera, E., Bigai, G., Bigoloni, A., Boffini, N., Borio, G., Bossolasco, S., Bruzzesi, E., Calabro, M. G., Calvisi, S., Campochiaro, C., Canetti, D., Canti, V., Castellani, J., Castiglioni, B., Cavalli, G., Cavallo, L., Cernuschi, M., Chiurlo, M., Cilla, M., Cinel, E., Cinque, P., Conte, C., Da Prat, V., Danise, A., De Lorenzo, R., De Luca, G., Dell'Acqua, A., Dell'Acqua, R., Della-Torre, E., Torre, L. D., Di Terlizzi, G., Dumea, I., Farolfi, F., Ferrante, M., Frangi, C., Fumagalli, L., Gallina, G., Germinario, B., Gianotti, N., Hasson, H., Lalla, F., Landoni, G., Lanzillotta, M., Voti, R. L., Mastrangelo, A., Messina, E., Moizo, E., Montagna, M., Monti, G., Morsica, G., Muccini, C., Nozza, S., Oltolini, C., Pascali, M., Patrizi, A., Pieri, M., Prestifilippo, D., Ramirez, G., Ranzenigo, M., Sapienza, J., Sartorelli, S., Seghi, F., Tambussi, G., Din, C. T., Tomelleri, A., Turi, S., Uberti-Foppa, C., and Vinci, C.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2021

31. European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations

Author

Lohr, J. -M., Beuers, U., Vujasinovic, M., Alvaro, D., Frokjaer, J. B., Buttgereit, F., Capurso, G., Culver, E. L., De-Madaria, E., Della-Torre, E., Detlefsen, S., Dominguez-Mu~noz, E., Czubkowski, P., Ewald, N., Frulloni, L., Gubergrits, N., Duman, D. G., Hackert, T., Iglesias-Garcia, J., Kartalis, N., Laghi, A., Lammert, F., Lindgren, F., Okhlobystin, A., Oracz, G., Parniczky, A., Mucelli, R. M. P., Rebours, V., Rosendahl, J., Schleinitz, N., Schneider, A., van Bommel, E. F. H., Verbeke, C. S., Vullierme, M. P., Witt, H., Besselink, M. G., Bruno, M. J., Czako, L., Chiaro, M., Filippova, O., Fukuda, A., Gaujoux, S., Hart, P. A., Hegyi, P., Jonas, E., Kahraman, A., Kleger, A., Kuryata, O., Laukkarinen, J., Lerch, M. M., Marchegiani, G., Marschall, H. -U., Matos, C., Molad, Y., Oguz, D., Pukitis, A., Satoi, S., Stone, J. H., Verheij, J., Vries, N., Lohr, J-Matthias, Beuers, Ulrich, Vujasinovic, Miroslav, Alvaro, Domenico, Frokjaer, Jens Brondum, Buttgereit, Frank, Capurso, Gabriele, Culver, Emma L., De-Madaria, Enrique, Della-Torre, Emanuel, Detlefsen, Sonke, Dominguez-Munoz, Enrique, Czubkowski, Piotr, Ewald, Nils, Frulloni, Luca, Gubergrits, Natalya, Duman, Deniz Guney, Hackert, Thilo, Iglesias-Garcia, Julio, Kartalis, Nikolaos, Laghi, Andrea, Lammert, Frank, Lindgren, Fredrik, Okhlobystin, Alexey, Oracz, Grzegorz, Parniczky, Andrea, Mucelli, Raffaella Maria Pozzi, Rebours, Vinciane, Rosendahl, Jonas, Schleinitz, Nicolas, Schneider, Alexander, van Bommel, Eric F. H., Verbeke, Caroline Sophie, Vullierme, Marie Pierre, Witt, Heiko, Besselink, Marc G., Bruno, Marco J., Czako, Laszlo, del Chiaro, Marco, Filippova, Oleksandra, Fukuda, Akihisa, Gaujoux, Sebastien, Hart, Phil A., Hegyi, Peter, Jonas, Eduard, Kahraman, Alisan, Kleger, Alexander, Kuryata, Olexander, Laukkarinen, Johanna, Lerch, Markus M., Marchegiani, Giovanni, Marschal, Hanns-Ulrich, Matos, Celso, Molad, Yair, Oguz, Dilek, Pukitis, Aldis, Satoi, Sohei, Stone, John H., Verheij, Joanne, de Vries, Niek, KKÜ, Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Löhr, Jm, Beuers, U, Vujasinovic, M, Alvaro, D, Frøkjær, Jb, Buttgereit, F, Capurso, G, Culver, El, de-Madaria, E, DELLA TORRE, E, Detlefsen, S, Dominguez-Muñoz, E, Czubkowski, P, Ewald, N, Frulloni, L, Gubergrits, N, Duman, Dg, Hackert, T, Iglesias-Garcia, J, Kartalis, N, Laghi, A, Lammert, F, Lindgren, F, Okhlobystin, A, Oracz, G, Parniczky, A, Mucelli, Rmp, Rebours, V, Rosendahl, J, Schleinitz, N, Schneider, A, van Bommel, Ef, Verbeke, C, Vullierme, Mp, Witt, H, and UEG guideline working, Group.

Subjects
Abdominal pain, IMMUNOGLOBULIN G4-RELATED DISEASE, SERUM IGG4 LEVELS, Medizin, Disease, RC799-869, Severity of Illness Index, immune-related cholangitis, Serology, 0302 clinical medicine, LONG-TERM OUTCOMES, Prednisone, Drug Dosage Calculations, Child, other organ involvement, STEROID-THERAPY, INTERNATIONAL-CONSENSUS, Evidence-Based Medicine, glucocorticoids, Gastroenterology, Induction Chemotherapy, IgG4-related, Diseases of the digestive system. Gastroenterology, PRIMARY SCLEROSING CHOLANGITIS, TYPE-1 AUTOIMMUNE PANCREATITIS, CONSENSUS DIAGNOSTIC-CRITERIA, Europe, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, diabetes mellitus, 030211 gastroenterology & hepatology, medicine.symptom, digestive, autoimmune pancreatitis type 1, Glucocorticoid, Immunosuppressive Agents, medicine.drug, Adult, medicine.medical_specialty, Digestive System Diseases, biomarkers, cancer, disease, Maintenance Chemotherapy, 03 medical and health sciences, Internal medicine, Diabetes mellitus, medicine, Humans, FINE-NEEDLE-ASPIRATION, Dose-Response Relationship, Drug, business.industry, EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY, Body Weight, Editorials, Cancer, Guideline, medicine.disease, business
Abstract

Frulloni, Luca/0000-0001-7417-2655; Hart, Phil/0000-0003-4346-6196; Capurso, Gabriele/0000-0002-0019-8753; de-Madaria, Enrique/0000-0002-2412-9541; Lohr, Matthias/0000-0002-7647-198X; Frokjaer, Jens Brondum/0000-0001-8722-0070 WOS:000542363500001 PubMed: 32552502 The overall objective of these guidelines is to provide evidence-based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)-related digestive disease in adults and children. IgG4-related digestive disease can be diagnosed only with a comprehensive work-up that includes histology, organ morphology at imaging, serology, search for other organ involvement, and response to glucocorticoid treatment. Indications for treatment are symptomatic patients with obstructive jaundice, abdominal pain, posterior pancreatic pain, and involvement of extra-pancreatic digestive organs, including IgG4-related cholangitis. Treatment with glucocorticoids should be weight-based and initiated at a dose of 0.6-0.8 mg/kg body weight/day orally (typical starting dose 30-40 mg/day prednisone equivalent) for 1 month to induce remission and then be tapered within two additional months. Response to initial treatment should be assessed at week 2-4 with clinical, biochemical and morphological markers. Maintenance treatment with glucocorticoids should be considered in multi-organ disease or history of relapse. If there is no change in disease activity and burden within 3 months, the diagnosis should be reconsidered. If the disease relapsed during the 3 months of treatment, immunosuppressive drugs should be added. National Societies Committee of the United European Gastroenterology (UEG) We gratefully acknowledge the support from the National Societies Committee of the United European Gastroenterology (UEG) for the conduct of these guidelines independent from other sources. No other funding was received.

Published
2020
Full Text
View/download PDF

32. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Author

Campochiaro C., Della-Torre E., Cavalli G., De Luca G., Ripa M., Boffini N., Tomelleri A., Baldissera E., Rovere-Querini P., Ruggeri A., Monti G., De Cobelli F., Zangrillo A., Tresoldi M., Castagna A., Dagna L (TOCI-RAF Study Group), Landoni G, DELLA TORRE , EMANUEL, Campochiaro, C., Della-Torre, E., Cavalli, G., De Luca, G., Ripa, M., Boffini, N., Tomelleri, A., Baldissera, E., Rovere-Querini, P., Ruggeri, A., Monti, G., De Cobelli, F., Zangrillo, A., Tresoldi, M., Castagna, A., Dagna, L (TOCI-RAF Study Group), Landoni, G, and DELLA TORRE, Emanuel

Subjects
Male, musculoskeletal diseases, medicine.medical_specialty, Multivariate analysis, Coronavirus disease 2019 (COVID-19), Efficacy, Pneumonia, Viral, macromolecular substances, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, Antiviral Agents, Article, Betacoronavirus, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Tocilizumab, Medical microbiology, Internal medicine, Intensive care, Internal Medicine, Humans, Medicine, 030212 general & internal medicine, skin and connective tissue diseases, Pandemics, Aged, Retrospective Studies, business.industry, Interleukin-6, Standard treatment, Oxygen Inhalation Therapy, COVID-19, Retrospective cohort study, Middle Aged, Receptors, Interleukin-6, Coronavirus, Outcome and Process Assessment, Health Care, chemistry, Italy, Cohort, Female, Safety, Coronavirus Infections, Respiratory Insufficiency, business
Abstract

Highlight • This is the first study comparing tocilizumab to standard of care in severe COVID-19 • Tocilizumab in severe COVID-19 patients did influence 28-day clinical outcomes • Tocilizumab safety was safisfactory except for ICU-admitted patients, Background : Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy. Methods : We performed a retrospective study on severe COVID-19 patients with hyper-inflammatory features admitted outside intensive care units (ICUs). Patients treated with intravenous TCZ in addition to standard of care were compared to patients treated with standard of care alone. Safety and efficacy were assessed over a 28-day follow-up. Results : 65 patients were included, 32 were of whose treated with TCZ. At baseline, all patients were on high-flow supplemental oxygen and most (78% of TCZ patients and 61% of standard treatment patients) were on non-invasive ventilation. During the 28-day follow-up, 69% of TCZ patients experienced a clinical improvement compared to 61% of standard treatment patients (p = 0.61). Mortality was 15% in the tocilizumab group and 33% in standard treatment group (p = 0.15). In TCZ group, at multivariate analysis, older age was a predictor of death, whereas higher baseline PaO2:FiO2 was a predictor of clinical improvement at day 28. The rate of infection and pulmonary thrombosis was similar between the two groups. Conclusions : At day 28, clinical improvement and mortality were not statistically significant different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials.

Published
2020

38. MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION

Author

G. De Luca, G. Cavalli, C. Campochiaro, DELLA TORRE E, P. Angelillo, A. Tomelleri, N. Boffini, S. Tentori, F. Mette, P. Rovere-Querini, A. Ruggeri, T. D’aliberti, P. Scarpelllini, G. Landoni, F. De Cobelli, J. F. Paolini, A. Zangrillo, M. Tresoldi, B. C. Trapnell, F. Ciceri, L. Dagna, De Luca, G., Cavalli, G., Campochiaro, C., DELLA TORRE, E, Angelillo, P., Tomelleri, A., Boffini, N., Tentori, S., Mette, F., Rovere-Querini, P., Ruggeri, A., D’Aliberti, T., Scarpelllini, P., Landoni, G., De Cobelli, F., Paolini, J. F., Zangrillo, A., Tresoldi, M., Trapnell, B. C., Ciceri, F., and Dagna, L.

Published
2020

40. Colchicine as a new therapeutic option for antithyroid arthritis syndrome

Author

Mancuso G., Boffini N., Dagna L., Della-Torre E., Mancuso, G., Boffini, N., Dagna, L., and Della-Torre, E.

Subjects
Adult, medicine.medical_specialty, Methimazole, business.industry, Arthritis, MEDLINE, Syndrome, medicine.disease, Dermatology, chemistry.chemical_compound, Rheumatology, chemistry, Antithyroid Agents, Colchicine, Medicine, Humans, Pharmacology (medical), Female, business
Published
2020

47. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli

Author

Della-Torre E., Campochiaro C., Cavalli G., De Luca G., Ciceri F., Zangrillo A., Dagna L., Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Ciceri, F., Zangrillo, A., and Dagna, L.

Subjects
inflammation, therapeutics, interleukin 1 receptor antagonist protein, anti-inflammatory agents, cytokines, non-steroidal
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results